Hepatitis Therapeutics Market Is Predicted To Grow Quickly Due To Rising Number Of Infected Population Till 2025: Grand View Research, Inc.

The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc. The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Browse full research report on Hepatitis Therapeutics Market: http://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market

Further Key Findings From the Report Suggest:

  • Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016
  • In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure. 
  • Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.
  • Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.
Browse more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/pharmaceuticals

Grand View Research has segmented the global hepatitis therapeutics market on the disease type, and region:

Hepatitis Therapeutics Disease Type Outlook (Revenue, USD Million, 2014 - 2025)
  • Hepatitis A
  • Hepatitis B
  • Hepatitis C
  • Others
Hepatitis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
  • Asia Pacific
    • China
    • Japan
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
Access Press Release By Grand View Research: http://www.grandviewresearch.com/press-release/global-hepatitis-therapeutics-market    
   
About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.


For more information: http://www.grandviewresearch.com

Comments

Post a Comment

Popular posts from this blog

Epigenetics Market to Observe Strong Development by 2022

The global  epigenetics market  is expected to reach USD 16.31 billion by 2022, according to a new report by Grand View Research, Inc. Growing worldwide prevalence of cancer and other diseases with epigenetic modification base is expected to drive market growth during the forecast period.  Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is expected to attract pharmaceutical companies to collaborate for the development of therapeutic drugs.  Presence of pipeline drugs and their expected commercialization is anticipated to boost penetration rates over the forecast period. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.  Technology advancements in the field of epigenetics especially pertaining to t
Read more

Increasing Incidences Of M&A Of CDMO/CRO With Big Pharma Companies To Drive Life Sciences BPO Market Growth Till 2024: Grand View Research, Inc.

Image
The  life sciences BPO market  is expected to reach USD 420 billion by 2024, according to a new report by Grand View Research, Inc. The lucrative growth is attributed to the growing demand for contract manufacturing of raw materials, Finished Dosage Forms (FDFs), medical devices, drug discovery services, regulatory services, pre-clinical and clinical trial services, and pharmacovigilance services.  The pharmaceutical and biotech industry invests heavily in the R&D sector to continuously introduce new molecules, devices, and treatments. The different stages of the drug development such as drug discovery, pre-clinical studies, and clinical trials require huge financial, technological, and human resources.  North America life sciences BPO market, by services, 2013 - 2024 (USD Billion) In order to cater to the growing needs of the industry, the outsourcing vendors are expanding their product and service offerings and they are targeting niche areas for long-term growth
Read more

U.S. Telehealth Market Is To Be $2.83 Billion By 2022: Grand View Research, Inc.

Image
U.S. telehealth market  is expected to reach USD 2.8 billion by 2022, according to a new report by Grand View Research Inc. Increasing access to basic healthcare is the major aim of telehealth along with improved healthcare quality and patient safety by early detection and diagnosis. According to a report published by the Agency for Health Care Research and Quality (AHRQ), implementation of telehealth solution improves quality of care delivery to patients.  The rising demand for self care and independent living along with the concept of home care is highly appealing to the population. The Rhode Island Partnership for Home Care reported that in 2014, over 20,000 citizens demanded for home care that led to approximately 1,000,000 visits by healthcare providers. Advantages that drive the higher adoption for home care include better psychological impact on patients, provision of friendly environment, care provision as per patient needs, and cost-effectiveness.  U.S. telehealth
Read more